HANGZHOU, China, March 26 /PRNewswire-FirstCall/ -- China Biopharma, Inc. (OTC Bulletin Board: CBPC) announced today that it has reached agreement with Beijing Keyuan Xinhai Pharmaceutical Company to launch newly approved pharmaceutical products made by leading international pharmaceutical companies. According to the agreement, China Biopharma will distribute pharmaceutical products made by international companies including human vaccines in China using its sales network and distribution logistics.
In the last few months, the company has made effort to extend its market scope and establish new partnership in addition to the original JV partner, Zhejiang Tianyuan Bio-pharmaceutical Co., Ltd. Due to certain local tax regulations the Company's sales of the products of its original JV partner could not be fully recognized. In order to effectively conduct its business operation and change from its passive marketing approach in China, the Company has shifted its market strategy to working more closely with new pharmaceutical products from global leading pharmaceutical companies in addition to local products. "We are very excited about the agreement we have reached with Beijing Keyuan Xinhai Pharmaceutical Company," said Mr. Qiumeng Wang, the Company's COO. "It will significantly improve our current operation situation." Beijing Keyuan Xinhai Pharmaceutical Company is one of the largest imported pharmaceutical product providers in China.
About China Biopharma, Inc.
China Biopharma Inc. is a biopharmaceutical company based in China.
Through its operating subsidiaries, the company develops and distributes
biopharmaceutical and pharmaceutical products throughout the world's most
populated country, China. Products include human vaccines and other
pharmaceutical drugs. Leveraging its local presents and the relationship
with local Chinese bio-pharmaceutical companies and international
biopharmaceutical companies, China Biopharma is building a
|SOURCE China Biopharma, Inc.|
Copyright©2008 PR Newswire.
All rights reserved